Дактилит при псориатическом артрите : особенности клинических проявлений, диагностика, иммунопатогенез и лечение
Аннотация
При обнаружении дактилита у больного псориатическим артритом (ПсА) необходимо как можно раньше назначить активное лечение, поскольку в отсутствие терапии наблюдается прогрессирование заболевания вплоть до эрозирования суставов и развития функциональных нарушений. В статье рассмотрены клинические признаки и диагностика ПсА, отмечена важность дифференциальной диагностики по этому признаку с другими воспалительными заболеваниями суставов. Указана необходимость выработки единых подходов к объективной оценке тяжести дактилита. Подробно описаны иммунопатогенез и основные направления его лечения, в том числе с использованием генно-инженерных биологических препаратов (ГИБП). Приведены данные клинических исследований, в которых оценивалась эффективность лечения дактилита и установлено, что использование ГИБП в большинстве случаев способствует существенному уменьшению не только выраженности его клинических признаков, но и сопутствующего отека костного мозга. Отмечено, что разработка новых патогенетических методов лечения, таргетных в отношении ряда установленных к настоящему времени биологически активных молекул, которые играют важную роль в патогенезе дактилита, будет способствовать повышению эффективности лечения больных ПсА.
Ключевые слова
Об авторах
Т. В. Коротаева
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522, Москва, Каширское шоссе, 34А
Россия
115522, Москва, Каширское шоссе, 34А
Е. Ю. Логинова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522, Москва, Каширское шоссе, 34А
Россия
115522, Москва, Каширское шоссе, 34А
Литература
1. Mease P, Gladman D, Helliwell P, et al. Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in Europen/North American dermatology clinics. J Am Acad Dermatol. 2014 Oct;71(4): 649-55. doi: 10.1016/j.jaad.2014.05.010. Epub 2014 Jun 25.
2. Oliveri I, Scarano E, Padula A, et al. Dactylitis, a term for different digit disease. Scand J Rheumatol. 2006 Sep-Oct;35(5): 333-40. doi:10.1080/03009740600906677.
3. Arendes R, Rahman P, Avina J, et al. What is the location of dactylitis in ankylosing spondylitis and psoriatic arthritis patients and how do they respond to anti-TNF treatment? Ann Rheum Dis. Jun 2016;75(Suppl 2):591. Doi: 10.1136/annrheumdis-2016-eular-4255.
4. Busquets-Perez N, Rodriguez-Moreno J, Gomez-Vaquero C, et al. Relationship between psoriatic arthritis and moderatesevere psoriasis: analysis of a series of 166 psoriatic arthritis patients selected from a hospital population. Clin Rheumatol. 2012 Jan;31(1):139-43. doi: 10.1007/s10067-011-1787-1. Epub 2011 Jun 24.
5. Scarpa R, Cosentini E, Manguso F, et al. Clinical and genetic aspects of psoriatic arthritis «sine psoriasis». J Rheumatol. 2003 Dec;30(12):2638-40.
6. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3(1):55-78.
7. Olivieri I, Padula A, Scarano E, et al. Dactylitis or «sausage-shaped» digit. J Rheumatol. 2007 Jun;34(6):1217-22.
8. Brockbank J, Stein M, Schentag C, et al. Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis. 2005 Feb;64(2):188-90. Epub 2004 Jul 22.
9. Andracco R, Zampogna G, Parodi M, et al. Dactylitis in gout. Ann Rheum Dis. Jan 2010;69(01):316. doi: 10.1136/ard2009.107755
10. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006 Aug;54(8):2665-73.
11. Gladman D. Psoriatic arthritis. Dermatol Ther. 2009 Jan-Feb;22(1):40-55. doi: 10.1111/j.1529-8019.2008.01215.x.
12. Payet J, Gossec L, Paternotte S, et al. Prevalence and clinical characteristics of dactylitis in spondylarthritis: a descriptive analysis of 275 patients. Clin Exp Rheumatol. 2012;30(2):191-6.
13. Kane D, Stafford L, Bresnihan B, et al. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003;42(12):1460-8.
14. Olivieri I, D’Angelo S, Padula A, et al. The challenge of early diagnosis of psoriatic arthritis. J Rheumatol. 2008;35(1):3-5.
15. Boehncke WH, Kirby B, FitzGerald O, et al. New development in our understanding of psoriatic arthritis and their impact on the diagnosis and clinical management of the disease. J Eur Acad Dermatol Venereol. 2014;28(3):264-70. doi: 10.1111/jdv.12222.
16. Scarpa R, Atteno M, Costa L, et al. Early psoriatic arthritis. J Rheumatol. 2009;83:26-7 (Suppl.) doi: 10.3899/jrheum.090217.
17. Gisondi P, Tinazzi I, Del Giglio M, et al. The diagnostic and therapeutic challenge of early psoriatic arthritis. Dermatol. 2010;221 1:6-14. Suppl doi: 10.1159/000316170.
18. Helliwell P, Firth J, Ibrahim G, et al. Development of an assessment tool for dactylitis in patients with psoriatic arthritis. J Rheumatol. 2005 Sep;32(9):1745-50.
19. Ferguson E, Coates L. Optimisation of rheumatology indices: dactylitis and enthesitis in psoriatic arthritis. Clin Exp Rheumatol. 2014 Sep-Oct;32(5 Suppl 85): S-113-7.
20. McGonagle D, Lories R, Tan A, et al. The concept of a “synovio-entheseal complex” and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum. 2007 Aug;56(8):2482-91.
21. Olivieri I, Padula A, D’Angelo S, et al. Role of trauma in psoriatic arthritis. J Rheumatol. 2016 Nov;43(11):2085-2087.
22. Laloux L, Voisin M, Allain J, et al. Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis. 2001 Apr;60(4):316-21.
23. Sherlock J, Joyce-Shaikh B, Turner S, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8-entheseal resident T cells. Nat Med. 2012 Jul 1; 18(7):1069-76. doi: 10.1038/nm.2817.
24. Tan A, Fukuba E, Halliday N, et al. High-resolution MRI assessment of dactylitis in psoriatic arthritis shows flexor tendon pulley and sheath-related enthesitis. Ann Rheum Dis. 2015 Jan;74(1):185-9. doi: 10.1136/annrheumdis-2014-205839. Epub 2014 Sep 26.
25. Kruithof E, Baeten D, De Rycke L, et al. Synovial histopathology of psoriatic arthritis, both oligo- and poly-articular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther. 2005;7(3): R569-80. Epub 2005 Mar 3.
26. Costello P, Winchester R, Curran S, et al. Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven. J Immunol. 2001 Feb 15;166(4):2878-86.
27. Yamamoto T, Yokozeki H, Nishioka K. Clinical analysis of 21 patients with psoriasis arthropathy. J Dermatol. 2005 Feb;32(2):84-90.
28. Costello P, Bresnihan B, O’Farrelly C, et al. Predominance of CD8+ T lymphocytes in psoriatic arthritis. J Rheumatol. 1999 May; 26(5):1117-24.
29. van Kuijk A, Reinders-Blankert P, Smeets T, et al. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis. 2006 Dec;65(12):1551-7. Epub 2006 May 25.
30. Noordenbos T, Yeremenko N, Gofita I, et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum. 2012 Jan;64(1): 99-109. doi: 10.1002/art.33396.
31. Raychaudhuri S, Raychaudhuri S, Genovese M. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem. 2012 Jan;359(1-2):419-29. doi: 10.1007/s11010-011-1036-6. Epub 2011 Sep 6.
32. Keijsers R, Joosten I, van Erp P, et al. Cellular sources of IL-17 in psoriasis: a paradigm shift? Exp Dermatol. 2014 Nov;23(11): 799-803. doi: 10.1111/exd.12487.
33. Fearon U, Griosios K, Fraser A, et al. Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol. 2003 Feb;30(2):260-8.
34. Yamamoto T. Angiogenic and inflammatory properties of psoriatic arthritis. ISRN Dermatol. 2013 May 30;2013:630620. doi: 10.1155/2013/630620. Print 2013.
35. Partsch G, Wagner E, Leeb B, et al. Upregulation of cytokine receptors sTNF-R55, sTNF- R75, and sIL-2R in psoriatic arthritis synovial fluid. J Rheumatol. 1998 Jan;25(1):105-10.
36. Spadaro A, Rinaldi T, Riccieri V, et al. Interleukin 13 in synovial fluid and serum of patients with psoriatic arthritis. Ann Rheum Dis. 2002 Feb;61(2):174-6.
37. Veale D, Ritchlin CH, FitzGerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005 Mar;64 Suppl 2:ii26-9.
38. Colucci S, Brunetti G, Cantatore F, et al. Lymphocyte and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis. J Pathol. 2007 May;212(1):47-55.
39. Ritchlin C, Haas-Smith S, Li P, et al. Mechanisms of TNF-alpha- and RANKLmediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest. 2003 Mar;111(6):821-31.
40. Yago T, Nanke Y, Kawamoto M, et al. IL-23 indices human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther. 2007;9(5):R96.
41. Chen L, Wei X, Evans B, et al. IL-23 promotes osteoclast formation by up-regulation of receptor activation of NF-kappaB (RANK) expression in myeloid precursor cells. Eur J Immunol. 2008 Oct;38(10): 2845-54. doi: 10.1002/eji.200838192.
42. De Dijke P, Krause C, de Gorter D, et al. Osteocyte-derived sclerosin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J Bone Joint Surg Am. 2008 Feb;90 Suppl 1:31-5. doi: 10.2106/JBJS.G.01183.
43. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007 Feb;13(2): 156-63. Epub 2007 Jan 21.
44. Rahimi H, Ritchlin CH. Altered bone biology in psoriatic arthritis. Curr Rheumatol Rep. 2012 Aug;14(4):349-57. doi: 10.1007/s11926-012-0259-1.
45. Geijer M, Lindqvist U, Husmark T, et al. The Swedish early psoriatic arthritis registry 5- year followup: substantial radiographic progression mainly in men with high disease activity and development of dactylitis. J Rheumatol. 2015 Nov;42(11):2110-7. doi: 10.3899/jrheum.150165. Epub 2015 Oct 15.
46. Mease PJ, Karki C, Palmer JB, et al. Clinical characteristics, disease activity and patient- reported outcomes in psoriatic arthritis patients with dactylitis or anthesitis: results from the Corrona psoriatic arthritis/Spondyloarthritis registry. Arthritis Care Res (Hoboken). 2017 Nov;69(11):1692-1699. doi: 10.1002/acr.23249.
47. Gladman D, Ziouzina O, Thavaneswaran A, et al. Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era. J Rheumatol. 2013 Aug;40(8):1357- 9. doi: 10.3899/jrheum.130163. Epub 2013 Jul 1.
48. Rose S, Toloza S, Bautista-Molano W, Helliwell P. Comprehensive treatment of dactylitis in psoriatic arthritis. J Rheumatol. 2014 Nov;41(11):2295-300. doi: 10.3899/jrheum.140879.
49. Ritchlin C, Kavanaugh A, Gladman D, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009 Sep;68(9): 1387-94. doi: 10.1136/ard.2008.094946. Epub 2008 Oct 24.
50. Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol. 2016 May;68(5):1060-71. doi: 10.1002/art.39573. Epub 2016 Mar 23.
51. Mease P, Gladman D, Ritchlin C, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005 Oct;52(10):3279-89.
52. Antoni C, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Int J Rheum Dis. 2017 Sep;20(9):1227-1236. doi: 10.1111/1756-185X.12645. Epub 2015 Jul 27.
53. McInnes IB, Kavanaugh A, Gottlieb A, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, doubleblind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013 Aug 31;382(9894):780-9. doi: 10.1016/S0140-6736(13)60594-2. Epub 2013 Jun 13.
54. Chimenti MS, Ortolan A, Lorenzin M, et al. Effectiveness and safety of ustekinumab in naive or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study. Clin Rheumatol. 2018 Feb;37(2):397-405. doi: 10.1007/s10067-017-3953-6. Epub 2018 Jan 4.
55. Kavanaugh A, Mease P, Gomez-Reino J, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014 Jun;73(6): 1020-6. doi: 10.1136/annrheumdis-2013-205056. Epub 2014 Mar 4.
56. Edwards C, Blanco F, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016 Jun;75(6):1065-73. doi: 10.1136/annrheumdis-2015-207963. Epub 2016 Jan 20.
57. Gladman D, Kavanaugh A, Gomez-Reino J, et al. Apremilast Treatment and Long-Term (156-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Analysis of a Large Database of 3 Phase III, Randomized, Controlled Trials [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10).
58. McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomized, double-blind, placebo-controlled, phase II proof-of- concept trial. Ann Rheum Dis. 2014 Feb;73(2):349-56. doi: 10.1136/annrheumdis-2012-202646. Epub 2013 Jan 29.
59. Patel N, Vera N, Shealy E, et al. A Review of the Use of Secukinumab for Psoriatic Arthritis. Rheumatol Ther. 2017 Dec;4(2):233-246. doi: 10.1007/s40744-017-0076-0. Epub 2017 Aug 28.
60. Mease P, McInnes IB. Kirkham B, et al. Secukinumab Inhibition of Interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015 Oct;373(14):1329-39. doi: 10.1056/NEJMoa1412679.
61. Коротаева ТВ, Новодережкина ЕА, Станислав МЛ и др. Применение ингибитора интерлейкина-17А секукинумаба при псориатическом артрите. Субанализ российской популяции международных рандомизированных клинических исследований FUTURE 1 и FUTURE 2. Научно- практическая ревматология. 2017;55(2): 151-8. [Korotaeva TV, Novoderezhkina EA, Stanislav ML, et al. Use of the interleukin- 17A inhibitor secukinumabin psoriatic arthritis: sub-analysis of Russian population of the international randomized clinical trials FUTURE 1 and FUTURE 2. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2017;55(2):151-8. (In Russ.)]. doi: 10.1007/s40744-016-0031-5.
62. McInnes I.B, Mease PJ Ritchlin CT, et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology (Oxford). 2017 Nov 1;56(11): 1993-2003. doi: 10.1093/rheumatology/kex301.
63. Коротаева ТВ. Результаты оценки сравнительной эффективности применения секукинумаба и адалимумаба в лечении псориатического артрита с использованием метода непрямого согласованного скорректированного непрямого сравнения. Современная ревматология. 2016;10(4):57-63. [Korotaeva TV. Results of evaluating the efficacy of secukinumab versus adalimumab in treating psoriatic arthritis by using the matching-adjusted indirect comparison method. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2016;10(4): 57-63. (In Russ.)]. doi: 10.14412/1996-7012-2016-4-57-63.
Для цитирования:
Коротаева Т.В., Логинова Е.Ю. Дактилит при псориатическом артрите : особенности клинических проявлений, диагностика, иммунопатогенез и лечение. Современная ревматология. 2018;12(1):5-12. https://doi.org/10.14412/1996-7012-2018-1-5-12
For citation:
Korotaeva T.V., Loginova E.Y. Dactylitis in psoriatic arthritis: clinical features, diagnosis, immunopathogenesis, and treatment. Modern Rheumatology Journal. 2018;12(1):5-12. (In Russ.) https://doi.org/10.14412/1996-7012-2018-1-5-12
Просмотров: 299
Послать статью по эл. почте 